Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exclusion: In the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment, such as rapidly progressive multiorgan failure.
This will be interesting. I'm curious if the investigator would simply disqualify a subject if he/she even thinks a subject won't be able to finish the trial thereby making our numbers more complete so to speak.
Interesting. Guess we'll see.
https://clinicaltrials.gov/ct2/show/NCT04784897
Not sure who else if flipping this pre-market but wow, these MM's are really picky!!
Easy to get fills but hard to get out. We know the offering is sitting at .85 but imo that really doesn't play into this until the market opens.
Anyway, news after close yesterday says the IND is like a year away. So not really a market mover imo. That's why I was taking advantage.
https://finance.yahoo.com/news/sonnet-announces-successful-completion-discovery-200100787.html
Either way, my chart senses tell me any gap here won't go unfilled. But THAT is only my opinion and not a buy/sell recommendation.
I was on other plays today, totally missed the .50's. Bought a bunch of .60's though. Was waiting for the chart to prove a bottom. Didn't see it yet but it can take off if it wants to!
$SONN
I'm not done buying yet
Yes, patience is key. And keeping eyes and ears open for data lock.
At least one of our end points isn't... "the patient is still alive".
And no, that wasn't meant to be funny. I was was just looking at another trial elsewhere that that was an endpoint.
https://clinicaltrials.gov/ct2/show/NCT04784897?term=brilacidin&draw=2&rank=2
Anyway, not listening to the noise, just waiting for data lock. 1 week later for top line data. That 1 week timeframe could see some pretty significant volatility!!! Not at all surprised to see attempts to shake out the weak hands.
KNOW WHAT YOU OWN IPIX'ers!!!
Message in reply to:
It's fine if you don't approve of the Company's handling of the trial or how many employee's they have, everything is relative. PPS will adjust as needed and the MM's are large and in charge until top-line results, which are imminent. NYSE has a few stable stock's I'm told.
Big things are happening for LXRX imo. Yes, revenue from licensing and royalties looks like. Their day is very close on the horizon.
https://www.lexpharma.com/pipeline
Made an excellent pre-market flip here. Keeping it on radar.
Good luck!!
Sorry to hear about the passing of anyone from this pandemic. I do agree the best data is from completed data. After the dust has settled that is. We're not even close to being at the end yet.
Though we remain hopeful that treatments and vaccines will win in the end.
Brilacidin needs to show it's worth to this effect. ASAP!!!!
Data lock and top line results immanent!!
Message in reply to:
It's difficult to say one way or another since one must first trust the numbers posted for us. Sadly, based on recent history I rarely trust anything other than the passage of time showing us truth in the end.
In the meantime, I don't hear about friends being sick. I'm guessing they stay home and don't mention it unless it gets bad.
This past week I had a friend tell me his unvaccinated brother passed from covid and another said her father passed the day after taking the moderna shot. I don't know underlying health conditions in either case.
The diversity of this IND makes sense and is actually somewhat exciting.
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division
https://ih.advfn.com/stock-market/NASDAQ/diffusion-pharmaceuticals-DFFN/stock-news/85935327/diffusion-pharmaceuticals-announces-clearance-of-i
I'm certainly no expert in the field but I do like what I'm seeing.
No, i didn't see it. This has been on my list for a while but haven't been keeping an eye on it. Watching LII's.
Good luck and congrats!!
btw, LXRX passing $5
Nice early volume!!
This is excellent news. Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
August 30 2021 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes the new recommendation by the European Society of Cardiology (ESC) to add SGLT inhibitors as part of the standard of care for the prevention and treatment of heart failure (HF). SGLT inhibitors have been given a Class IA recommendation-- the strongest endorsement-- in updated clinical practice guidelines released by the ESC Heart Failure working group in the EU at its annual meeting, the ESC Congress 2021 - The Digital Experience.
Specifically, the guidelines recommend the following for the primary prevention of HF in patients with risk factors for its development:
“SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with diabetes at high risk of cardiovascular (CV) disease or with CV disease in order to prevent HF hospitalizations.”
The guidelines recommend the following for the treatment of patients with HF and diabetes or for the treatment of diabetes in HF:
“SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with type 2 diabetes mellitus (T2DM) at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.”
“SGLT2 inhibitors (dapagliflozin, empagliflozin, and sotagliflozin) are recommended in patients with T2DM and heart failure with reduced ejection fraction (HFrEF) to reduce hospitalizations for HF and CV death.”
The guidelines also addressed worsening heart failure, noting:
“The combined SGLT-1 and 2 inhibitor, sotagliflozin, has also been studied in patients with diabetes who were hospitalized with HF. The drug reduced CV death and hospitalization for HF.”
“Safety and better outcome have also been recently shown in a prospective randomized trial with sotagliflozin in diabetic patients hospitalized for HF, irrespective of their left ventricular ejection fraction (LVEF).”
“It is quite rare for an investigational drug to be listed in the guidelines prior to regulatory approval and we do not take the trust and confidence that ESC has placed in sotagliflozin lightly,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer at Lexicon. “We know patients with heart failure suffer reduced quality of life and remain at high risk of hospitalization or death, and these new guidelines are a strong call to action to ensure patients receive the most effective therapies for acute and chronic heart failure. We continue to work diligently for these patients and plan to submit a New Drug Application with the U.S. Food and Drug Administration later this year for its review of sotagliflozin, as a therapy for people suffering from heart failure and living with type 2 diabetes.”
The full 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure can be found at escardio.org.
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched. Sotagliflozin is not approved for use in any other indications, including heart failure.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s clinical development of and regulatory filings for sotagliflozin and the therapeutic and commercial potential of sotagliflozin. This press release also contains forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Inquiries:
Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com
Sooner, rather than later, this bubble will catch many off guard.
https://twitter.com/NorthmanTrader/status/1431895485208481794?s=19
Just knowing it's there and being aware helps imo.
Just as nothing goes straight up, same goes for on the way down. For me, it's all about volatility.
Couldn't stop myself, locked in some green here. 4.50"s.
Sweet!
Just saw this as one of your pinch picks. Interesting. Share structure is about maxed out. They either RS or increase. Anyway, nuff of dat, looks to bounce soon imo. But I'd be watching the daily list as well.
Cheers.
Liking the curves on the daily...
SNGX daily.
See if it holds the $.
I marked this puppy right at the bottom and still didn't take a position.
Watching.
I don't listen to those so called "analysts". They post their jargon long after a stock has already proven their potential imo, making their analysis pretty much worthless. Most of the time anyway. And many of them are hedging when they release to trap retail.
There's NO trust in the markets. Especially these days.
NEWS: Inpixon Secures Purchase Order for Hundreds of High-End, Next-Generation, Multi-Tech RF Sensors for U.S. Federal Government
https://finance.yahoo.com/news/inpixon-secures-purchase-order-hundreds-133000009.html
Message in reply to:
NEWS: https://finance.yahoo.com/news/inpixon-ostendo-announce-collaboration-reimagine-133000096.html
This is some real futuristic technology with potential military applications imo.
I've been adding for a bit now. Check out the technical side setting up for the pinch.
INPX daily
Stellar results would make it happen!!
NEWS: https://finance.yahoo.com/news/inpixon-ostendo-announce-collaboration-reimagine-133000096.html
This is some real futuristic technology with potential military applications imo.
I've been adding for a bit now. Check out the technical side setting up for the pinch.
INPX daily
"FINAL COUNTDOWN!" Data lock is imminent, any day now.
Would be a trip if Leo doesn't announce data lock and just goes all out with top line data. Which, according to his PR, would only be a week later. Such a short timeframe it'd be wise not to announce data lock. Could be a major target for market manipulation.
Nah, That never happens. Especially in bioland.
GO IPIX!!
I'll sticky his post.
Message in reply to:
JFM, your post should be sticked. Brilacidin's mechanism of action and how it was designed is at the core of our confidence that the C-19 trial results will be stellar. We are in the final countdown to success.
Clock's ticking. Data lock coming very soon imo. 1 week after, top line data? We'll see. And we're looking at quite the potential run up to that data.
.60+ sure doesn't seem far fetched to me. Not one iota.
IPIX
$IPIX daily
Message in reply to:
It should be at .60+ Before the phase 2 trial results given severity of pandemic. Really a bit shocking and sad sitting at market cap of $110m when this is an obvious cure to Covid. That means everyone has a clear 10x ride up to 1 billion
Buckle
Up
Data lock PR tomorrow
UC ph2 start of trial PR any day now too!
People going to make loads of money here as soon as they release the data. A company with 2 phase 2s surely
Should be sitting at $500m mc without any data! Upside is massive here
I take these offerings as a necessary evil in bioland. The offering may be closed but it'll take time to float that many shares. Good news can certainly speed it up, but they'll be dishing it out to retail until they're done and out. So, until we get something decent, technically or fundamentally, we are where we are imo.
But, just between you N me, I was looking closer at the charts to see if I'd take another bite and wait it out. Thinking Friday afternoon unless it breaks lower before then. Summer's about over so I'm leaning to September before something decent comes along.
Back over $4. Looking pretty imo. Low only went to 3.31.
4.08
Has the cup, needs the handle and some volume to go with it.
imo
SONN daily
Need the small squeeze to turn into THE BIG SQUEEZE!!
The bid is certainly holding strong looks like.
Thanks for the alert Night Stalker! I didn't think to check for the form 4 filings...
http://www.openinsider.com/search?q=bxrx
If I had I may have added more. I loaded .58's just last week! I'm thinking in about a month or less this may be back over the $. BUT, that's just a WAG.
GLTA!
Early volume!
We'll see if .85 is the final price. Chances are the buyers will negotiate it lower, and still get their discount
Offerings in bio land are very common. But it'll take time for the dilution to get absorbed by retail. Good solid news always helps. We'll see if they get some.
Thinking anticipation will take this closer to resistance. Watching to close above the 20dma >.30.
What's incredible is there aren't more shareholders crying wolf. Maybe there are and they're talking to their lawyers.
Let me explain.
Monday and Tuesday, though a bit above the previous week volume doesn't draw attention. Wednesdays volume was unimpressive though it was easy to see there was an aggressive takedown with about a .18 price range. Watching the intradays action it was clear, to me, that a shake out was taking place. It was more than just saying bad news was coming. Did someone know something? There was the potential of receiving a delisting notice which did come through. Maybe that was the cause of the sell off. Maybe.
Lets take a look at the price/volume for the week...
Date Open High Low Close* Adj Close* Volume
Aug 20, 2021 0.6600 0.6700 0.6000 0.6300 0.6300 52,093,500
Aug 19, 2021 1.6000 2.0700 1.1300 1.2200 1.2200 209,850,000
Aug 18, 2021 0.8400 0.9100 0.7300 0.7500 0.7500 3,382,600
Aug 17, 2021 0.8600 0.8700 0.8200 0.8500 0.8500 1,188,500
Aug 16, 2021 0.9900 0.9900 0.8500 0.8800 0.8800 1,097,100
So, the morning of the 19th there was an immediate gap even before retail had a chance to do anything.
Pre-Market High $2.62 (05:51:42 AM)
Pre-Market Low $0.9039 (04:13:42 AM)
Where do these pre PRE market trades come from? Not your typical broker. Though your broker does have the ability to tell you which exchange they did go thru. I've nailed down the Pacific Exchange for another stock in the past.
SONN's Float 19.51M
https://finviz.com/quote.ashx?t=sonn
Thursday's volume... 209,850,000
Wow right?
Conspiracy? Nah, business as usual right?
NOT in my opinion. Was there a pump? I didn't see one anywhere.
It's my opinion that there was a control group (hedge fund) out there that's been accumulating and on Monday they slipped the word out to their few "friends" that Wednesday would be their last chance before the gap up.
Take a moment to read this article...
https://www.nytimes.com/2021/08/16/business/short-seller-wall-street-scams-hindenburg.html
A good read right? IF you didn't take the time to read it I suggest you take the time to at least scan it. There's talk of naked shorts and all kinds of manipulation out there. Was SONN at all involved in this? Probably not. There's plenty of manipulation out there.
SONN announced a .85 raise for $30M on the 19th. Interesting eh?
https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-pricing-30-013500497.html
On August 19, 2021, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for the last 30 consecutive business days preceding the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum of $35,000,000 required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”).
The Notice has no immediate effect on the listing of the Company’s common stock and the Company’s common stock continues to trade on The Nasdaq Capital Market under the symbol “SONN.”
Under Nasdaq Listing Rule 5810(c)(3)(C), the Company has until February 15, 2022 (the date that is 180 calendar days following the date of the Notice) to regain compliance with the MVLS Requirement (the “Compliance Period”). To regain compliance, the MVLS must close at $35,000,000 or more for a minimum of 10 consecutive business days during the Compliance Period.
Does SONN have the potential to regain compliance by Feb 15th?
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
https://finance.yahoo.com/news/sonnet-biotherapeutics-provides-fiscal-2021-103000156.html
Of course we do our own DD.
SONN daily
SONN daily with a different view
My opinion is my own.
SONN totally needs to set up again. This wicked whiplash was crazy. Killed a lot of longs imo.
THIS MARKET MANIPULATION IS NUTS!
There's a hedge fund out there that did it imo. Creating a major dip to steal shares and then a major market gap to sell right into unsuspecting retail. Read an interesting article about just that the other day. Sooner or later they'll be figured out. I think the article was about Nate Anderson and his company Hindenburg Research, you may want to do some dd. But yeah, it gets crazy out there. What happened to The Real Stock Market?
SONN daily
Again My opinion.
This is PART of how they were able to gap AND TRAP this so easily yesterday...
Shs Float 19.51M
Shs Outstand 22.15M
https://finviz.com/quote.ashx?t=sonn
This would only happen in pre-market or after hours where stop loss and stops aren't in play.
Low floats make for an easy target, especially during pre market.
My post from the 18th...
Message in reply to:
This is where I watch the charts more closely. Jump ship? No, watch for the bottom to set and watch for the bounce. The way this market has been I'm a bit more than 50% cash. I'm ready. This is just how I play, everyone has their own risk level.
So many bios have been just trashed this earnings period, way under valued imo. I'm adding slowly till they set up for the rebound.
Message in reply to:
Possible bounce into the close. This looks more like a shake out than bad news coming.
Filled a few .77. Still need to see a solid bottom.
Trying to psych everyone out with their S-1 filing.
Message in reply to:
See my previous post. MM's controlling this. Longs got slaughtered, MM's were hunting stop losses. But to each their own. Betting on delisting NOTICE is a gamble.
Shorty better keep a sharp eye open.
See what tomorrow brings.
Message in reply to:
you called it to ah *T* , i liked fer many moons. thanks fer your upbeat chat.
'Sonnet BioTherapeutics Inc (SONN)'
Message in reply to:
I recognized it for what it was, could have been wrong of course. But certainly had no idea they would gap the crap out of this. It could have taken a week to move back up. And we still don't know why.
I locked in some nice gains but I'm also watching the show go on.
Message in reply to:
2.62 high pre-market. Very interesting indeed.
Consolidated Last Sale $2 +1.2549 (+168.42%)
Pre-Market Volume 13,704,572
Pre-Market High $2.62 (05:51:42 AM)
Pre-Market Low $0.9039 (04:13:42 AM)
https://www.nasdaq.com/market-activity/stocks/sonn/pre-market
This is why i said yesterday it looked to be more of a shake out.
Have a nice day!!!
Still waiting for the news, but I'll ride free till then.
Short squeeze this puppy!!!!!
The whole plan is that we make more money than we lose. Do I plan on being in this next year? Who knows. Coulda just moved on yesterday but I was seeing more volatility here in the short term.
Oh, are we supposed to believe in the company? They only have to keep getting things right for that to happen. And while bio's take time between events they lend themselves to manipulation by who knows who playing with the pps.
Have a nice weekend mick, I should visit your board more often. BTW, marked (followed) you yesterday or the day before. Cheers.
Looking forward to seeing SONN actually recover on its own over the manipulation we saw yesterday and Wednesday, which IN MY OPINION SONN had absolutely nothing to do with. They'll regain compliance before February IN MY OPINION. So, I'm here to make money.
End of story.
I was selling pre market yesterday from $2 all the way down to the 1.60's during open market. I only kept a few "do or die shares' to see what would happen.
They are no longer "do or die" they are now all long. And I'm still green after averaging down what little I have left from my profits.
"Been buying .64's all the way to .70. Green to you!!!"
That doesn't even match up to your previous reply
"Just a few do or die shares"
Sounds to me like you got stuck from yesterday.
Been buying .64's all the way to .70. Green to you!!!
See what shorty does here
Offering at .85 eh? bounce from the .50's?
https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-pricing-30-013500497.html